GLP-1 Watchdog

What GLP-1 Watchdog does

GLP-1 Watchdog is an independent consumer comparison platform focused exclusively on GLP-1 receptor agonist weight-loss programs in the US market. Founded in March 2026 by Eduard Cristea, the site reviews and ranks approximately 30 to 41 telehealth providers, evaluating them on cost, safety, and legitimacy. It targets the roughly 30 million Americans currently using GLP-1 medications — and particularly the 24 million who lost commercial insurance coverage for these drugs in 2025-2026 — by surfacing online telehealth options priced between $69 and $299 per month against brand-name pricing of $998 to $1,349 per month. Medically reviewed content is overseen by Dr. A. Goher, MD.

The platform's core offering is a curated database of telehealth providers with side-by-side pricing, state-by-state coverage data, and a suite of more than 10 interactive tools. It also covers pipeline GLP-1 candidates including Orforglipron and Retatrutide. Technical infrastructure includes an llms.txt endpoint that exposes provider, pricing, and coverage data in a machine-readable format, suggesting early-stage productization of the data layer for AI-agent consumers. The platform is web-based, free to end users, and operates without disclosed institutional funding.

The business model is media-based. Revenue is generated through affiliate commissions from featured telehealth providers, routed via the Katalys performance marketing network, supplemented by display advertising. The site is founder-owned, privately held, and has no disclosed parent company, institutional investors, or funding rounds. As of mid-2026, the company is preparing editorial coverage for the Medicare Bridge Program launching in July 2026 at approximately $50 per month, which would open a senior demographic distinct from the existing cash-pay commercial GLP-1 market.

Name

GLP-1 Watchdog

Legal name

GLP-1 Watchdog

Website

https://glp1watchdog.com

Company type

Private

Founded year

2026

Operating status

Operating

Short description

GLP-1 Watchdog is an independent consumer comparison platform that reviews and ranks US telehealth providers offering GLP-1 weight-loss medications, helping cash-pay consumers compare cost, safety, and legitimacy across online programs and brand-name options.

Ownership category

akta.pro rank

Product category

Consumer Health Comparison Platform

akta.pro primary industry

Risk Stratification, Early Warning Scores & Predictive Analytics (HLACAGAE)

Keywords

• GLP-1 medication comparison
• Telehealth provider reviews
• Weight loss medication guides
• Drug price comparison
• Consumer health advocacy

GTM type

B2C

Offering type

Digital Commerce or Content

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Affiliate Commissions: Primary revenue source. GLP-1 Watchdog earns referral commissions when readers click affiliate links to GLP-1 providers and subsequently sign up or make purchases. Commissions disclosed on every page. No additional cost to readers - same price whether visiting provider directly or through affiliate link.
2. Display Advertising: Display advertisements may appear on the site. Advertising placement does not influence editorial content or provider ratings.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

GLP-1 Watchdog is an independent consumer comparison platform that ranks and reviews 30+ telehealth providers offering GLP-1 weight loss medications (Ozempic, Wegovy, Mounjaro, Zepbound). The site provides independent scoring (Safety 30%, Transparency 25%, Cost 20%, Support 15%, Speed 10%), interactive tools (cost calculator, drug comparison builder, journey tracker, provider match quiz), and educational content covering safety alerts, scam detection, insurance/Medicare navigation, and side effect management. All content is free to consumers, with revenue generated through affiliate commissions from partner telehealth providers.

Product overview

GLP-1 Watchdog is a consumer protection and comparison platform for GLP-1 weight loss medications, operating as a unified content and tools platform. The core offering consists of independent provider rankings and reviews (scoring 34+ telehealth programs on safety, transparency, cost, support, and speed), supported by a suite of interactive tools including the Cost Calculator, Weight Loss Predictor, Savings Calculator, Medicare Eligibility Checker, Insurance Checker, Side Effect Tracker, Provider Match Quiz, GLP-1 Journey Tracker, and Drug Comparison Builder. The platform also provides educational content through its Safety Center, GLP-1 Scam Checker, State Medicaid Coverage Map, and a comprehensive guides library covering GLP-1 mechanisms, side effects, and pipeline medications. A machine-readable data endpoint (/llms) provides structured provider data for programmatic access.

Differentiator

Problem solved

Functional benefit

Products and services

• Provider Rankings & Reviews Independent evaluation and ranking of GLP-1 telehealth providers with detailed reviews scored on Safety 30%, Transparency 25%, Cost 20%, Support 15%, and Speed 10% across 34+ reviewed programs. For consumers researching safe, affordable GLP-1 medications.
• Cost Calculator Interactive tool that calculates real monthly GLP-1 costs based on medication type, dosage, and coverage situation to help consumers find affordable options.
• Weight Loss Predictor Month-by-month weight loss projection tool based on GLP-1 medication type and user-provided starting data.
• Savings Calculator Interactive tool that calculates potential savings from switching GLP-1 providers or medications by comparing current costs against alternatives.
• Medicare Eligibility Checker Tool to determine whether users qualify for the Medicare GLP-1 Bridge Program ($50/month coverage starting July 2026).
• Insurance Checker Interactive tool to verify whether the user's insurance plan covers GLP-1 medications and what alternatives are available.
• Side Effect Tracker Personal tracker for logging GLP-1 side effects to help users understand if symptoms are normal and when to consult a provider.
• Provider Match Quiz Six-question personalized recommendation quiz matching users with optimal GLP-1 providers based on budget, insurance status, and health goals.
• GLP-1 Journey Tracker

Quantifiable outcome

• Compounded GLP-1 programs verified by GLP-1 Watchdog save consumers $650-$1,280/month compared to brand Ozempic ($998/month list)
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Novo Nordisk (Hims Partnership)minorStrategic or Co-development Partner · 9 March 2026Novo Nordisk dropped patent infringement lawsuit against Hims & Hers and instead partnered - Hims agreed to stop advertising compounded GLP-1s. Part of broader GLP-1 market legal settlement landscape.
• KatalyscoreGTM or Marketing PartnerPerformance marketing network for health and wellness providers. GLP-1 Watchdog participates in Katalys affiliate network for tracking and commission payments from partner GLP-1 providers.

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• GoodRx: Largest US consumer drug price-comparison and coupon platform. Comparable in business model (free consumer site monetizing via affiliate/transaction fees) and in educating consumers on prescription affordability — the closest analog in the GLP-1 cost-comparison space.
• Drugs.com: Major consumer drug information and comparison site (FDA label data, side effects, interactions, pill identifier). Comparable information-aggregation and tool-building approach for medications such as Ozempic/Wegovy.
• WebMD: Largest consumer health information publisher. Operates editorial content, drug comparison, and provider-finding tools on an ad/affiliate model at scale — the established incumbent against which any consumer health watchdog site is benchmarked.
• Healthline: Major consumer health editorial site with extensive GLP-1 coverage and medically reviewed content. Comparable in content depth and medical-reviewer model, differs in monetization (display + content licensing vs. affiliate).

Direct peers

• SingleCare: Prescription drug price comparison and discount platform with a free consumer model and affiliate relationships to pharmacies and providers. Operates with the same 'show consumers the cheapest path to fill a prescription' GTM as GLP-1 Watchdog.
• RxSaver: Drug price comparison and coupon site owned by RetailMeNot. Functions as a direct affiliate-driven consumer comparison site for prescription medications, overlapping with GLP-1 Watchdog on cost transparency and provider redirection.
• Zocdoc: Consumer-facing provider search and booking platform with verified reviews and appointment booking. Shares the affiliate/lead-gen model and 'match patients to providers' use case.
• Sesame: Cash-pay telehealth marketplace offering direct-to-consumer pricing and provider matching with no-insurance-required positioning. Operates adjacent to the GLP-1 provider ecosystem GLP-1 Watchdog ranks.

Others

• Hims & Hers Health: Direct-to-consumer telehealth company and one of the most prominent GLP-1 providers. Reviewed on GLP-1 Watchdog and a peer in the broader GLP-1 telehealth category, though it operates as a provider rather than a comparison site.
• Ro: Direct-to-consumer telehealth platform offering GLP-1 weight-loss programs among other services. A primary participant in the GLP-1 telehealth space that GLP-1 Watchdog ranks and reviews.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GLP-1 Watchdog